Research

A Phase II Tolerability Trial of Neoadjuvant Docetaxel with Carboplatin and Capecitabine in Locally Advanced Breast Cancer


 

ABOUT THE AUTHORS

Aruna Mani, MD; Sandra X. Franco, MD; Grace Wang, MD: Neil Abramson, MD; Lee S. Schwartzberg, MD: James Jakub, MD; Elizabeth Tan-Chiu, MD: Alisha Stein, RNC, BSN, OCN; Alejandra T. Perez, MD; and Charles L Vogel, MD.

Affiliations: Dr. Mani is a breast medical oncologist at Memorial Cancer Institute, Pembroke Pines, FL. Dr. Franco is now Chief of Oncology at the Oncology Center, Clinica del Country, Bogota, Colombia. Dr. Wang is an oncologist at Advanced Medical Specialties, Miami, FL. Dr. Abramson is Clinical Professor of Medicine and Emeritus Director of Education and Research at Baptist Cancer Institute, University of Florida, Jacksonville, FL. Dr. Schwartzberg is Medical Director of The West Clinic, Memphis, TN. Dr. Jakub is now Assistant Professor of Surgery, Division of Gastroenterology and General Surgery, Mayo Clinic, Rochester, MN. Dr. Tan-Chiu is Medical Director of Florida Cancer Care, Davie, FL. Dr. Schwartz is Principal Investigator at Mount Sinai Medical Center, Miami Beach, FL. Ms. Frankel is Director of Oncology Clinical Research and Development at Memorial Cancer Institute, Hollywood, FL. Dr. Krill-Jackson is an oncologist at Mount Sinai Comprehensive Cancer Center, Miami, FL. Ms. Stein is now Oncology Clinical Coordinator at Genentech Inc., Fort Lauderdale, FL. Dr. Perez is Director of the Breast Cancer Center at Memorial Cancer Institute, Hollywood, FL. Dr. Vogel is Professor of Clinical Medicine and Director of the Women’s Center, Sylvester Comprehensive Cancer Center, Deerfield Beach, FL.

Conflicts of interest: Dr. Vogel has served as an advisor and is a member of the speakers’ bureaus of sanofi-aventis U.S. and Roche, as well as many other companies whose products were not part of the current study plan. The other authors have no pertinent conflicts of interest to disclose.

Pages

Recommended Reading

Eribulin Extends Survival of Women With Heavily Pretreated Breast Cancer
MDedge Hematology and Oncology
Techniques Compared for Breast Tumor Detection
MDedge Hematology and Oncology
Clinical Trial Participation Tied to Improved Breast Cancer Outcomes
MDedge Hematology and Oncology
Bone Micrometastases Show No Survival Impact in Early Breast Cancer
MDedge Hematology and Oncology
NCCN Breast Guidelines Stand by Bevacizumab
MDedge Hematology and Oncology
Sequencing Reveals MAP3K1 Mutation in Luminal-Type Breast Cancer
MDedge Hematology and Oncology
Radioactive Seeds Guide Surgeons to Nonpalpable Breast Lesions
MDedge Hematology and Oncology
Genentech Appeals to FDAs Regulatory Flexibility on Avastin
MDedge Hematology and Oncology
CDER: Avastin Breast Cancer Claim Undermines Approval Process
MDedge Hematology and Oncology
Low Vitamin D Associated With Poor Prognostic Features in Breast Cancer
MDedge Hematology and Oncology